Oneness Biotech Co., Ltd. (4743.TWO)
- Previous Close
59.10 - Open
60.00 - Bid 62.30 x --
- Ask 62.00 x --
- Day's Range
60.00 - 62.40 - 52 Week Range
51.40 - 184.00 - Volume
1,919,321 - Avg. Volume
2,520,203 - Market Cap (intraday)
29.829B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-2.44 - Earnings Date May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2023
- 1y Target Est
308.00
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
www.onenessbio.comRecent News: 4743.TWO
View MorePerformance Overview: 4743.TWO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4743.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4743.TWO
View MoreValuation Measures
Market Cap
28.25B
Enterprise Value
21.64B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
239.65
Price/Book (mrq)
2.30
Enterprise Value/Revenue
183.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.68%
Return on Equity (ttm)
-8.45%
Revenue (ttm)
117.93M
Net Income Avi to Common (ttm)
-1.17B
Diluted EPS (ttm)
-2.44
Balance Sheet and Cash Flow
Total Cash (mrq)
7.02B
Total Debt/Equity (mrq)
3.18%
Levered Free Cash Flow (ttm)
-320.32M